That's the strange thing at CHM and IMU. The slides look impressive, the FDA is paving a smooth path, here and there one complete response and yet, the industry players won't touch it. The 2 CEOs got the right connections and still, no interest at all. Funding becomes a big problem. Whoever was lined up in May / June pulled the plug, no replacement could be found. Emergency solution: the recent cap raising. Pretty sure sh gave the green light today but what happens next?
The CORE NK and the GBM CAR-T data haven't helped at all and CDH 17 won't do anything until at least 6 patients have been dosed by March - May and even then, it is only a small chance to attract some of Dr Bec's pharma friends.
About 600-650m shares to hit the market this or early next week. Let's see if all, who signed up, will really pay. And even if yes, some will off load at anything above 0.8c. Then the same amount of 0.8c oppies, a second cap raising and 1.7b shares that wants to be sold.
CHM like IMU need the validation of big pharma to convince the market they got something great. And even that, like RAD, is no guarantee.
A lot must go right for CHM and so far nothing did. Miracles can happen overnight but will it happen here too?
There are other bio-tech stories where $$$$ gets thrown at them if management does the right things. Have a look at OCC, their strategy worked out well.
GLTA
CHM Price at posting:
1.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)